Trial reportFrontiers in medicine2026
Minimum effective concentration of ropivacaine for ultrasound-guided pericapsular nerve group block to relieve spinal anesthesia positioning pain in elderly patients with femoral intertrochanteric fracture: a double-blind biased-coin dose-finding study.
Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal ropivacaine concentration for ultrasound-guided pericapsular nerve group (PENG) block to relieve spinal anesthesia positioning pain in elderly patients with femoral intertrochanteric fracture remains unclear. We aimed to estimate the minimum effective concentration (MEC) and explore concentration-related motor impairment. Methods: In this double-blind biased-coin up-and-down study, elderly patients scheduled for spinal anesthesia underwent ultrasound-guided PENG block with 20 mL ropivacaine. The initial concentration was 0.10%. For a successful block, the subsequent patient was assigned to the same concentration (probability = 0.89) or a 0.05% lower concentration (probability = 0.11). For a failed block, the concentration was increased by 0.05% for the next patient. The trial was terminated when 45 successful blocks were achieved. Block success was defined as a pain score ≤ 3 at rest and during passive leg raise 30 min after block. The primary outcome was MEC90 estimated by isotonic regression. Secondary outcomes included MEC50, concentration-specific success rates, quadriceps weakness, and onset time of analgesia. Results: Fifty-two patients completed the sequential trial. Isotonic regression estimated MEC90 at 0.25% (95% CI, 0.20%-0.30%) and MEC50 at 0.20% (95% CI, 0.20%-0.20%). Success rates were 0% at 0.10% and 0.15%, 89.5% at 0.20%, 96.0% at 0.25%, and 100% at 0.30%. Quadriceps weakness at 6 h increased with concentration, occurring in 5.3% at 0.20%, 36.0% at 0.25%, and 50.0% at 0.30% (trend Conclusions: In elderly patients with femoral intertrochanteric fracture receiving ultrasound-guided PENG block with a fixed 20 mL volume of ropivacaine, the prespecified isotonic regression-estimated MEC90 for relieving spinal anesthesia positioning pain was 0.25%. Exploratory safety analyses suggested that quadriceps weakness at 6 h was more common at concentrations ≥0.25%, but these analyses were underpowered and hypothesis-generating. Future studies should determine whether modifying volume, concentration, or total dose can preserve analgesia while reducing motor impairment. Clinical trial registration: identifier ChiCTR2500102032.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.